High-throughput screening ... In particular, industry scientists have proprietary 'virtual screening' programs that can test millions of compounds without dipping a single pipet tip.
In this webinar, our guest speaker will present a case study for the discovery of four non-nucleoside small molecules that bind favorably to SARS-CoV-2 RdRp over the active form of the popular drug ...
In this study, we developed a proof-of-concept immunotherapy screening platform harnessing tumoroids to validate the cytotoxic activity of Natural Killer (NK) cells. Tumoroids were genetically ...